(Q53399727)

English

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr

scientific article published on 23 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

semaglutide

5 May 2024

author name string

Vanita R Aroda

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Stephen C Bain

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Bertrand Cariou

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Milivoj Piletič

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Ludger Rose

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Mads Axelsen

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Everton Rowe

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

J Hans DeVries

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

publication date

23 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

355-366

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient perspectives on once-weekly medications for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Standards of medical care in diabetes--2014

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930085-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30085-2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/28344112

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53399727&oldid=2145716850"